Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT04419558 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

372

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Pamrevlumab
DRUG: Placebo

Sponsor

Kyntra Bio